Macular degeneration trials in United States

In United States 95 Also abroad 220

95 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
Where
Durham
Age
50 years to 89 years
People
100
Run by
Duke University
See details and how to joinNCT06619405
Phase 1/2Taking people
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Where
Erie
Age
55 years to 80 years
People
62 worldwide
Run by
Kriya Therapeutics, Inc.
See details and how to joinNCT06765980
Phase 2/3Taking people
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Where
Appleton, Asheville, Beaufort, Bellaire, Bellevue, Bloomfield, Cary, Colorado Springs, Danbury, Denver, Edina, Encino, Erie, Florence, Fort Myers, Fort Worth, Gilbert, Great Neck, Hagerstown, Hickory, Hixson, Johnson City, Joliet, Katy, Knoxville, Ladson, Lemont, Lenexa, Louisville, Manchester, Mountain View, Nashville, Orlando, Portland, Pueblo, Roanoke, Rochester, Round Rock, Salem, San Antonio, San Marcos, Santa Ana, Sarasota, Schertz, Springfield, Wake Forest, Waterford, West Columbia, West Des Moines, West Jordan, Winter Haven
Age
50 years and over
People
960 worldwide
Run by
EyeBiotech Ltd.
See details and how to joinNCT07496567
Phase 2Enrolling by invitation
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Where
Albuquerque, Augusta, Bakersfield, Baltimore, Beverly Hills, Boston, Edina, Germantown, Mountain View, Nashville, Philadelphia, Phoenix, Poway, Reno, Santa Barbara, The Woodlands
People
116
Run by
AbbVie
See details and how to joinNCT05210803
Phase 1Taking people
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Where
Austin, Dallas, East Weymouth, Lakewood, The Woodlands
Age
50 years and over
People
54 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07230834 · EU 2025-521758-40-00
Phase 2Taking people
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
Where
‘Aiea, Bakersfield, Deerfield Beach, Fort Lauderdale, Fullerton, Jacksonville, Lemont, Phoenix, Teaneck, The Woodlands, West Columbia
Age
50 years and over
People
15
Run by
Adverum Biotechnologies, Inc.
See details and how to joinNCT07630649
No phaseTaking people
Effects of Goji vs. Fiber on Macular Degeneration
Where
Sacramento
Age
65 years to 95 years
People
60
Run by
University of California, Davis
See details and how to joinNCT06237127
Phase 1/2Taking people
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Where
Abilene, Carmel, Dallas, Reno, The Woodlands
Age
50 years and over
People
66
Run by
AbbVie
See details and how to joinNCT07160179
No phaseTaking people
Visual Remapping to Aid Reading With Field Loss
Where
Minneapolis
Age
16 years and over
People
108
Run by
University of Minnesota
See details and how to joinNCT03848663
Phase 3Taking people
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Where
Austin, Bakersfield, Fort Lauderdale, Hagerstown, Santa Barbara, Waterford, West Columbia
Age
50 years and over
People
850
Run by
Ocular Therapeutix, Inc.
See details and how to joinNCT07516132
No phaseTaking people
Stem Cell Ophthalmology Treatment Study II
Where
Coral Springs, Westport
Age
18 years and over
People
500 worldwide
Run by
MD Stem Cells
See details and how to joinNCT03011541
Phase 2Taking people
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Where
Abilene, Albuquerque, Augusta, Austin, Bakersfield, Baltimore, Bayonet Point, Beaufort, Bellaire, Bloomfield, Bonita Springs, Campbell, Carmel, Cherry Hill, Chevy Chase, Cleveland, Dallas, Danbury, Edison, Encino, Eugene, Fullerton, Gilbert, Great Neck, Greenville, Hagerstown, Huntington Beach, Indianapolis, Katy, Kingston, Ladson, Lakewood, Long Island City, Longmont, Lynchburg, Madison, McAllen, Mesa, Metairie, Mt. Pleasant, Nashville, Oak Park, Orlando, Oxnard, Pensacola, Philadelphia, Phoenix, Pinellas Park, Portland, Poway, Round Rock, Salt Lake City, San Antonio, San Marcos, Santa Ana, Schertz, Scottsdale, Sioux Falls, Southlake, Springfield, St. Petersburg, Tampa, The Woodlands, Toms River, Torrance, Towson, Tyler, Walnut Creek, West Jordan, Winter Haven
Age
60 years and over
People
240
Run by
Apellis Pharmaceuticals, Inc.
See details and how to joinNCT07215390
No phaseEnrolling by invitation
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Where
Bellaire, Boston, Salt Lake City
Age
50 years and over
People
88 worldwide
Run by
Perceive Biotherapeutics, Inc.
See details and how to joinNCT07660640
No phaseTaking people
Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).
Where
Salt Lake City
Age
65 years to 90 years
People
50
Run by
University of Utah
See details and how to joinNCT07582042
No phaseTaking people
Village-Integrated Eye Worker Trial II
Where
San Francisco
Age
60 years and over
People
60,200
Run by
University of California, San Francisco
See details and how to joinNCT03752840
No phaseNot yet taking people in United States
Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension
Where
Los Angeles
Age
55 years to 75 years
People
32
Run by
Stanford University
See details and how to joinNCT07605468
No phaseTaking people
Inherited Retinal Degenerative Disease Registry
Where
Columbia
People
20,000
Run by
Foundation Fighting Blindness
See details and how to joinNCT02435940
Early phase 1Taking people
The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma
Where
Worcester
Age
50 years to 100 years
People
50
Run by
MCPHS University
See details and how to joinNCT06593405
No phaseTaking people
Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss
Where
Boston
Age
14 years and over
People
12
Run by
New England College of Optometry
See details and how to joinNCT07577219
No phaseTaking people
Adaptive Optics Imaging of Outer Retinal Diseases
Where
Bethesda, Silver Spring
Age
21 years and over
People
100
Run by
Food and Drug Administration (FDA)
See details and how to joinNCT05355415
No phaseTaking people
High Resolution Retinal Imaging
Where
Philadelphia
Age
7 years and over
People
600
Run by
University of Pennsylvania
See details and how to joinNCT01866371
No phaseTaking people
Strategies for Improving Linkage-to-Care After Eye Disease Screening
Where
San Francisco
Age
60 years and over
People
3,000
Run by
University of California, San Francisco
See details and how to joinNCT06943599
No phaseTaking people
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
Where
San Francisco
Age
55 years and over
People
80
Run by
University of California, San Francisco
See details and how to joinNCT07556406
Phase 4Enrolling by invitation
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
Where
Tyler
Age
18 years and over
People
236
Run by
Harrow Inc
See details and how to joinNCT07456826
Phase 2Taking people
MMP-9 Inhibition for Recalcitrant Wet AMD
Where
Iowa City
Age
50 years to 99 years
People
50
Run by
University of Iowa
See details and how to joinNCT04504123